Lab TestedOzempic 1mg/3ml 1 Pen by Novo Nordisk
Ozempic (semaglutide 1 mg/3 ml) is a prefilled subcutaneous pen that functions as a selective GLP-1 receptor agonist, engaging the endogenous incretin signalling axis to regulate postprandial glucose excursions, attenuate gastric motility, and sustain appetite suppression across a full weekly dosing interval. A C18 fatty-acid side chain anchors semaglutide to circulating albumin, conferring a plasma half-life of approximately 165–168 hours and enabling true once-weekly receptor engagement with minimal peak-to-trough fluctuation. Every Ozempic pen is released only after HPLC content verification, LAL endotoxin screening, and batch-level GMP compliance review at Novo Nordisk's certified manufacturing facilities.

